Celsion's liver-cancer therapy may extend survival

|About: Celsion Corporation (CLSN)|By:, SA News Editor

Celsion's (CLSN) ThermoDox treatment for hepatocellular carcinoma (HCC), the most common type of liver cancer, may significantly improve overall survival rates in patients.

The conclusion comes from the post-hoc analysis of the Phase III HEAT Study of ThermoDox; a year ago, the company said that ThermoDox failed in its primary goal of progression-free survival.

Celsion believes that the latest data supports the continued Phase III testing of ThermoDox.

Shares are +4.4%. (PR)